Gilead Sciences (GILD) just cleared an important milestone: its once daily bictegravir and lenacapavir combo matched Biktarvy in the Phase 3 ARTISTRY 2 trial, with clean safety data that strengthens ...
Wondering if Gilead Sciences is still a smart buy after its big run, or if the stock has already priced in the good news? Here is a breakdown of whether the current share price really lines up with ...
So far five companies have agreed to the terms. They are Pfizer, Eli Lilly, AstraZeneca, Novo Nordisk and EMD Serono, which ...
While autologous therapies are mainstream in blood cancers, experts warn against overhyping allogeneic and in vivo approaches ...
Gilead Sciences (NASDAQ: GILD) has outperformed the market over the past 20 years by 2.66% on an annualized basis producing an average annual return of 11.48%. Currently, Gilead Sciences has a market ...
The annual Morrow County Chamber of Commerce Parade was held Dec. 5 in Mount Gilead. As for the floats in this year’s parade, ...
Israeli cybersecurity company Cyera, founded by Yotam Segev (CEO) and Tamar Bar-Ilan (CTO), has tripled its valuation within ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback